The Mach7 (ASX:M7T) share price is rising: Here’s why

The Mach7 Technologies Ltd (ASX:M7T) share price is currently up after its contract win, with a business called Advocate Aurora.

You’re reading a free article on Rask. Join 4,000+ Australians who get our expert advice, tools, exclusive research and investment recommendations. Get your 30-day trial for $1! Learn more

The Mach7 Technologies Ltd (ASX: M7T) share price is currently up after its contract win, with a business called Advocate Aurora.

Mach7 is an ASX company that specialises in medical imaging solutions for healthcare providers.

Mach7’s contract win with Advocate Aurora

The company revealed that it has licensed its eUnity universal viewing solution to Advocate Aurora Health (AAH).

This license contract is valued at $4.3 million, which includes a software license fee, professional services and an initial five-year support term. Of this value, Mach7 expects to recognise between $1.5 million to $1.7 million in FY22. The rest is expected to be recognised evenly from FY23 to FY27.

The contract provides for volume expansion pricing and the ability for AAH to extend the initial term at agreed pricing.

AAH currently uses the Mach7 ‘Vendor Neutral Archive’ (VNA) for storage and image data management. This agreement extends Mach7’s product presence at AAH with the Mach7 eUnity Viewer which will serve as a universal viewer for multiple departments across the AAH network.

The eUnity viewer will also be deployed as a full diagnostic viewer, and in conjunction with Mach7’s universal worklist, will serve as a back-up PACS (picture archiving and communication system) solution for downtime occurrences, including planned maintenance and unplanned events.

Management comments

Mach7 CEO Mike Lampron 

online pharmacy minocin for sale no prescription pharmacy

said: “I am delighted that AAH continues to expand its partnership with Mach7 to execute their enterprise imaging strategy. With the Mach7 VNA already installed, the eUnity viewing solution will give AAH the ability to access and view any image, anywhere, and serves as another great example of the additional value Mach7 can bring to our customers through the acquisition of Client Outlook. This contract is a great start to the new financial year and is a strong continuation of the strong sales momentum we saw in FY21.”

Summary thoughts on the Mach7 share price

online pharmacy zoloft for sale no prescription

The Mach7 share price has dropped around 33% over the last five months. So if you’ve been looking to pick up shares, then this low price could be opportunistic whilst it continues to win contracts.

I don’t know enough about the business to say if today’s price is great value, but if it keeps growing its market share then it could be one of the ASX growth shares to keep an eye on.

CSL, Xero, ANZ... the ASX is beaten up

Right now, only brave investors are buying. Is ASX Reporting Season your KEY opportunity to act? Buy, or sell.

This coming Monday night, our two most experienced professional investors, Owen Rask and Leigh Gant, are hosting an exclusive and rare webinar on the what to watch this ASX reporting season. LIVE and free

With over 35 years of combined investing experience, join our Chief Investment Officer and Head of Content for our free Q&A.

We’ll be diving into results from CSL, Pro Medicus (ASX: PME), ANZ Bank and more. It’s absolutely free to join us. Take advantage of this volatility with our free playbook. Simply click here to view the topics.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.

A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

How can Rask help you?

About Rask

Learn more about us, our your community and our mission.

Rask investing philosophy

Nearly 15 years later.
It's still a work in progress.

Online investment community

You won't find our investment community on Facebook or Reddit because it's secure, free and available now.

Join 250,000+ podcast listeners

250,000 investors tune into the Rask podcasts every month. Find out why.

Find a financial planner

Australia's financial experts. At your doorstep.

Free finance courses

35,000 students have enrolled in free Rask courses. We're on a mission to 100,000.

Subscribe to Rask's free investor newsletter

53,000 Australian investors subscribe to our Sunday newsletter... and love it! It's free.

$50 million invested

We manage almost $50 million on behalf of Aussies. Discover how you can invest with us.

Better investing starts here.

Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best  insights.

Subscribe to Rask's free investor newsletter

Kick off your week with our pick of podcasts, courses and investing resources to keep your finger on the Rask pulse!

Here you go: A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.